other material
confidence high
sentiment positive
materiality 0.75
Elicio publishes Phase 1 ELI-002 data in Nature Medicine: OS 28.94 months, 77% risk reduction
Elicio Therapeutics, Inc.
- At 19.7 mo median follow-up, median OS increased to 28.94 months from 16.33 months in Phase 1 AMPLIFY-201.
- Above-threshold T cell responses gave 77% reduction in death risk (HR 0.23) and 88% reduction in relapse risk (HR 0.12).
- 84% (21/25) of patients had tumor biomarker responses; 24% (6/25) achieved complete biomarker clearance.
- Final event-driven DFS analysis for Phase 2 AMPLIFY-7P study of ELI-002 7P in PDAC anticipated Q4 2025.
- ELI-002 was well tolerated; no dose-limiting toxicities or ≥Grade 3 treatment-related adverse events observed.